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Abstract:  The annual worldwide suicide rate currently averages approximately 13 per 
100,000 individuals per year (0.013% per year), with higher average rates for men than for 
women in all but a few countries, very low rates in children, and relatively high rates in 
elderly men. Suicide rates vary markedly between countries, reflecting in part differences 
in case-identification and reporting procedures. Rates of attempted suicide in the general 
population average 20–30 times higher than rates of completed suicide, but are probably 
under-reported. Research on the relationship between pharmacotherapy and suicidal 
behavior was rare until a decade ago. Most ecological studies and large clinical studies 
have found that a general reduction in suicide rates is significantly correlated with higher 
rates of prescribing modern antidepressants. However, ecological, cohort and case-control 
studies and data from brief, randomized, controlled trials in patients with acute affective 
disorders have found increases, particularly in young patients and particularly for the risk 
of suicide attempts, as well as increases in suicidal ideation in young patients. whether 
antidepressants are associated with specific aspects of suicidality (e.g., higher rates of 
completed suicide, attempted suicide and suicidal ideation) in younger patients with major 
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affective disorders remains a highly controversial question. In light of this gap this paper 
analyzes research on the relationship between suicidality and antidepressant treatment.  
Keywords: suicidal risk; antidepressants; pharmacotherapy; younger patients 
 
1. The Complex Challenge of Suicide 
The annual worldwide suicide rate currently averages approximately 13 per 100,000 individuals per 
year (0.013% per year), with higher average rates for men than women in almost all countries, low 
rates in children, and relatively high rates in elderly men [1–4]. Suicide rates vary markedly among 
regions of the world, countries and locales, in part reflecting differences in case-identification and 
reporting procedures [2,5]. Estimated rates of attempted suicide are much less reliable than for 
completed suicide. Rates of attempted suicide in the general population average 20–30 times higher 
than rates of completed suicide, but are probably under-reported. Suicide attempts range widely in 
method and seriousness of intent [6,7]. The ratio of attempts/suicides in clinical samples of mood-
disorder patients is much lower, suggesting a greater lethality of suicidal behaviors [8]. Most cases of 
suicide (81%–95%) in the general population involve psychiatric illnesses, nearly half of which 
(48.5%) are mood disorders [9]. Internationally, the overall average suicide rate has been rising 
gradually over the past half-century, with increases reported in about half of the nations, mainly among 
men, and moderate decreases found in the other half, including Northern Europe and North America. 
These improvements could reflect improved diagnosis and treatment of mood disorders during the 
same period [4,10–13]. The risk of completed suicide within five years is twice as high among men 
than women (8.3% vs. 4.3%), as expected, and most occurred within a year of follow-up by a 
psychiatric hospital [14]. The ratio of attempts to subsequent suicides (A/S) also was half as great in 
men as in women (12:1 vs. 23:1), consistent with the greater lethality of suicide actions in men. The 
risk of subsequent suicide was higher in men below the age of 35 versus above the age of 35 (9.7% vs. 
7.0%), but higher in women older than this age than those below this age (6.0% vs. 2.5%). 
Accordingly, the relative risk among younger men was four-times higher than in younger women 
(9.7% versus 2.5%), whereas the relative risk in older men and women did not differ much (7.0% 
versus 6.0%), indicating that the lethality of suicidal behavior in women over age 35 approaches that 
of men of similar age. Suicide rates are surprisingly high among persons diagnosed with anxiety 
disorders [15,16].  
Severe anxiety may accompany suicidal behavior [17], but the evidence that anti-anxiety 
medications reduce suicidal risk in anxiety disorder patients is very limited [16]. The general risk 
factors for suicide include the presence of a major mood disorder with hopelessness, especially when 
co-occurring with alcohol or substance abuse [2,6,9,18]. The risk is especially high among young, 
impulsive-aggressive and older unmarried men [2,3]. The risk of suicide in bipolar patients continues 
to be high, despite the introduction of a growing number of new treatments. Tondo, Lepri, and 
Baldessarini [19] suggested that the risk of dying by suicide among bipolar disorder patients is nearly 
10%, assuming potential risk-exposures of 60 years or more. More than one-third of all suicidal acts 
occurred within the first year from illness-onset, and more than half within the first five years of Pharmaceuticals 2010, 3               
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illness, indicating the need for early diagnosis and intervention in major mood disorders. 
Approximately three-quarters of the unresolved morbidity among bipolar disorder patients is a result of 
depression [20–23], and this, no doubt, encourages high rates of utilization of antidepressants as a 
treatment option, even though such treatment is neither approved by regulatory bodies, nor well 
supported by available clinical research as either effective or safe in bipolar patients [24,25]. 
Furthermore, antidepressant treatments are associated in some patients with dysphoric-mixed-agitated 
or psychotic states that can increase suicidal risk [26–28]. The effects of treatments on suicidal risk 
have been a topic of growing research interest in recent years, but evidence that most modern 
psychiatric treatments reduce long-term suicide risks is very limited [2,3,29–31]. In view of this gap, 
the present chapter will systematically review whether the use of antidepressants is associated with 
benefits in terms of completed or attempted suicide and whether the increasing use of SSRIs is 
associated with benefits in terms of decreased rates of suicide, with the aim of generating evidence-
based suggestions for clinicians. 
In order to provide an overview of research antidepressants and suicide risk, we performed careful 
MedLine, Excerpta Medica, PsycInfo and Index Medicus searches to identify all papers and book 
chapters in English during the period 1965–2010. The search terms used were “suicide”, “suicidal”, 
“suicidality” and all suicide-related terms, “antidepressants”, “antidepressant agents”, “selective 
serotonin reuptake inhibitors (SSRI)”, “Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)” 
“noradrenergic and specific serotonergic antidepressants (NaSSA)”, “selective noradrenaline reuptake 
inhibitor (NaRI),” “Norepinephrine and Dopamine Reuptake Inhibitor (NDRI)” “tricyclics (TCA)”, 
and “Monoamine oxidase inhibitor (IMAO)”. Where a title or abstract seem to describe a study 
eligible for inclusion, the full article was obtained and examined to ascertain its relevance based on the 
inclusion criteria. Any discrepancies between the two reviewers who, blind to each other, examined the 
studies for possible inclusion, were resolved by consultations with senior authors. The combined 
search strategies yielded over 500 abstracts. After a complete analysis of the abstracts, 200 full-text 
articles were reviewed. Approximately 130 studies met our inclusion criteria and were included, 
focusing on the most recent studies for the present review. 
2. Antidepressants and Suicidal Risk 
Only recently has the effect of antidepressant treatments on suicidal behavior and the increased 
overall mortality associated with major psychiatric disorders become a focus of research interest 
[32,33,34]. A highly controversial question is whether antidepressant treatment modifies the risk of 
various aspects of “suicidality” among patients with major depressive disorders [35–41], especially 
whether the selective serotonin reuptake inhibitors (SSRIs) may cause worsening of suicidal thoughts 
in vulnerable people [42,43].  
In 2005, a systematic review of published randomized controlled trials comparing SSRIs with other 
active treatments or placebo found an almost 2-fold increase in the odds of fatal and nonfatal suicide 
acts among those exposed to SSRIs [44]. However, no increased risk was observed when only fatal 
suicide acts were included. Among adolescents, a recent study found that SSRIs utilization 
significantly increased the risk of completed or attempted suicide [45] whereas, among adults, SSRI Pharmaceuticals 2010, 3               
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use significantly decreased the risk of completed or attempted suicide and, among people aged 65 or 
more years, the use of SSRIs had a significant protective effect [45].  
Another systematic review by Gunnell et al. [46] compared the use of SSRIs and placebo in adults 
with depression and other clinical conditions and showed no evidence of increased risk of completed 
suicide and only weak evidence of increased risk of non-fatal self-harm. More recently, the U.S. Food 
and Drug Administration (FDA) performed a meta-analysis of individual patient data from 372 
randomized placebo-controlled trials of antidepressants, with a total of nearly 100,000 patients, and 
reported that suicidal behavior was strongly related to age [47]. The risk associated with antidepressant 
use relative to placebo was increased among patients aged 25, or younger whereas it was reduced 
among patients aged 65 or more. The risk among adult patients aged 25–64 years was not significant, 
but it was reduced when suicidal ideation and behavior were considered together [48]. Based on these 
findings, in 2007 the FDA ordered that all antidepressant drugs carry an expanded black-box warning 
on their label that included information about the increased risk of suicidal behavior in young adults 
aged 18–24 years [49,50].  
O'Leary  et al. [51] reviewed suicide rates in affective disorder patients and the impact of the 
electroconvulsive  therapy (ECT) era vs. the antidepressant era in 75 follow-up studies. Suicide 
accounted for more than 12% of all deaths in samples in which 40% or more of patients had died. They 
found that suicide rates decreased with longer follow-up periods; the mean suicide rate was 6.3 per 
1,000 for the pre-treatment era, 5.7 per 1,000 for the ECT treatment era (1940 to 1959) and 3.3 per 
1,000 for the antidepressant treatment era (from 1960 on). They concluded that the utilization of ECT 
and antidepressants may have contributed to this decrease, although other variables may be involved. 
One important limitation to take into account is that the trials included by FDA were not primarily 
designed to measure any particular suicidal behavior. Instead they used a composite outcome of 
suicidal ideas, preparatory acts, suicide attempts and deaths by suicide [48]. Additionally, of all 
suicidal events that were reported, less than 30% were serious suicide attempts or deaths. Furthermore, 
considering that suicidality was self-reported rather than observed by others in the majority of the 
clinical trials, it is possible that antidepressant treatment, particularly in younger subjects enhanced 
communication about suicidality, which may promote more articulated and open thoughts and 
behaviours.  
Most of studies on the effect of antidepressant therapy on the risk of suicide have a number of other 
additional limitations. First, observational studies have limited ability to adjust for baseline differences 
and are prone to bias and confounding. Also, among adolescents, SSRI treatment is often reserved for 
the very severe cases, and so the higher suicide rate might be confounded by severity, that is, 
adolescents who received SSRIs might have been more severely depressed (or more suicidal) than 
adolescents who did not receive SSRIs. In contrast, among adults, SSRIs may be prescribed for both 
severe and less severe cases, and confounding might be less important. Only a few studies have 
considered confounding factors such as the severity of the illness for which the antidepressant 
medication was prescribed.  
Barbui et al [45] argued that, although re-analyses of randomized studies, including the FDA study, 
reported similar differences between antidepressants [50,52,53], it is not clear why the use of only 
certain antidepressants, such as paroxetine and venlafaxine, increases the risk of suicide more than 
others. They suggested that new evidence such as head-to-head comparisons are needed to test Pharmaceuticals 2010, 3               
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properly the long-term efficacy and safety of those medications in clinical practice, particularly in 
younger patients.  
In Europe, the European Medicines Agency (EMEA) has ruled that SSRIs and selective serotonin 
and norepinephrine reuptake inhibitors (SNRIs) should not be prescribed for depression in children and 
adolescents under the age of 18. The Committee for the Safety of Medicines in the UK has advised that 
the balance of risks and benefits for the treatment of depression in the pediatric population is 
unfavourable for most SSRIs. 
In recent years, to explore this issue, many different types of studies have been performed, 
including ecological analyses, observational studies, case-control studies and randomized clinical 
trials.  
3. The Relationship between Antidepressants and Suicide as Reported in Ecological Studies 
The evidence that antidepressant treatment yields reductions in the risk of suicides or attempts at the 
national level is controversial. Research suggests that in most of the Nordic countries and in the USA, 
the use of modern antidepressants over the past decade in clinical practice was associated with 
generally moderate decreases in overall suicide rates, varying by sex and age groups [10,11,13,54–61]. 
However, in the USA and some Nordic countries, similar trends regarding a reduction of suicide rates 
were also reported a decade before the introduction of fluoxetine, the first clinically successful modern 
antidepressant [13,61].  
Sebestyen et al. [62] conducted a time trend analysis investigating the correlation between the 
trends of antidepressant prescriptions and suicide rates and a seasonality index (the extent of the 
seasonality in suicide rates) in Hungary between 1998 and 2006. They found that increasing 
antidepressant utilization was associated with a significantly decreased seasonality of suicides only 
among males.  
Recently Baldessarini et al. [13] reported that only nine of 29 ecological studies reported significant 
inverse correlations between increased use of modern antidepressants and declining trends in suicide 
rates. Six found no relationships and 14 found inconsistent correlations over sex or age subgroups.  
Data from 78 reporting countries indicated that only about half (54%) experienced decreases in their 
suicide rates between the 1950s (when antidepressants were not available) and the early 2000s (a 
decade after introduction of modern antidepressants); 46% reported increases in their suicide rates. 
Similar inconsistencies in the suicide rate trends were found in each region (Western and Eastern 
Europe, Latin America and Asia). The distribution of decreasing and increasing suicide rates of nations 
between 1990 and the early 2000s was similar [4]. These data suggest that trends in suicide rates are a 
highly complex phenomenon which reflects the existence of many contributing factors.  
Kalmar et al. [63] analyzed annual antidepressant prescription rates and suicide rates of about 10 
million inhabitants between 1999–2005 by age and gender in Hungary. They reported that the suicide 
rate was inversely related to the increased utilization of antidepressants in both males and females. The 
antidepressant prescription rate was also related to suicide rate even after controlling for many 
variables such as the divorce rate and the unemployment rate, although not after controlling for the 
alcohol consumption rate. Pharmaceuticals 2010, 3               
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Ecological studies should be considered in light of several limitations. First, it is possible that 
improvements in public health, changes in legal, cultural or social prohibitions against suicide and 
improvements in identifying and reporting suicides might be associated with higher suicide rates 
despite the increased access to modern psychopharmacological treatment. Socioeconomic factors may 
also contribute to the complex findings from the ecological studies, as well as access to clinical 
services and social support. Finally, all correlational studies suffer from a fundamental inability to 
relate medication exposure or other specific factors causally to suicidal behavior at the level of 
individuals [64].  
Ecological studies cannot indicate a direct, causal relationship between antidepressant treatment and 
reduced suicidal risk at the level of individual persons, and further research with less ambiguous 
methods are needed. 
4. The Relationship between Antidepressants and Suicide as Reported in Cohort and  
Case-Control Studies 
Data from the cohort and case-control studies suggest that the utilization of antidepressants 
markedly increased during the 1990s, but in recent years their utilization has decreased as a result of 
concerns regarding the emergence of suicidality during antidepressant treatment.  
Recently, Schneeweiss et al. [65] conducted a cohort study of users of antidepressant agents in a 
population of 287,543 adults aged 18 years and older after the initiation of antidepressant treatment. 
They found rates of suicidal behavior ranging from 4.41 per 1,000 person-years to 9.09 per 1,000 
person-years, and the majority of events occurred in the first six months after treatment initiation. 
Compared with selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, 
tricyclic agents, and other newer agents showed a similar risk. They supported the US Food and Drug 
Administration's decision to treat all antidepressants alike in their advisory, and they suggested that 
clinicians should be vigilant in monitoring patient behavior after initiating treatment with 
antidepressant agents. 
Bailly [66] suggested that, relative to placebo, SSRIs are efficacious for paediatric patients with 
affective disorders but may be associated with a modest increase in the risk of occurrence of suicidal 
ideation and behaviour. However, he argued that their utilization is also associated with a significant 
decrease in the suicide rates in children and adolescents, presumably because of their efficacy, 
compliance, and low toxicity in overdose. Recent research suggests that antidepressants may be 
protective against early readmission after hospitalization for suicide attempts or ideation [67]. These 
data, taken together, indicates that SSRIs can improve adolescent depression better than placebo [68], 
although the magnitude of the antidepressant effect is 'small to moderate' because of a high placebo 
response. 
Considerable recent attention and wide-scale interventions by regulatory authorities have changed 
drug usage patterns. In a 9-year cohort study 20,906 children who were placed on antidepressant 
therapy, Schneeweiss et al. [69] found that 266 attempted suicide and three completed suicide, with no 
meaningful differences in the rates in patients given different SSRIs. They supported the decision of 
the Food and Drug Administration to include all antidepressants in the black box warning regarding Pharmaceuticals 2010, 3               
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the potentially increased suicidality risk for children and adolescents who begin the use of 
antidepressants. 
The same authors [69] suggested that treatment decisions should be based on the medication’s 
efficacy, and clinicians should be vigilant in monitoring patients after initiating therapy with any 
antidepressant. In fact, in a cohort study of 287,543 adults aged 18 years and older who used 
antidepressants, they found that most suicidal events occurred in the first six months after treatment 
initiation. There was no clinically meaningful variation in the rates of suicide and suicide attempt 
between the different antidepressants.  
In conclusion, the increased risk of suicidality in adolescents, compared to adults, is small, but 
consistent across most studies, although epidemiological studies do not support a clear relationship 
between use of antidepressants and the completed suicide rate [68]. Reeves and Ladner [70] suggested 
that antidepressant-induced suicidality was an uncommon occurrence but also a legitimate 
phenomenon. Close monitoring is needed, and adequate follow-up care should be provided for patients 
after initiation of a new antidepressant. 
Other sources of data about this controversial topic include large cohorts of depressed patients from 
general practice or health-maintenance organizations, and relatively large, case-control comparisons of 
subgroups varying in exposure to antidepressants. Such studies include over one million, mainly 
clinically depressed, subjects in 17 reports [71–87]. These studies have yielded inconsistent findings. 
Many (n = 11) were designed to test for greater suicidal risk with SSRI antidepressants compared to 
other agents or to non-treatment. Nine of these 11 studies did not find evidence of greater suicidal risk 
associated with antidepressant treatment, and a majority of the other studies (4 out of the 6) found 
decreased or no difference in suicidal risk with more antidepressant treatment.  
A few of these studies found greater suicidal risk with more antidepressant treatment in general or, 
specifically, with the greater use of SSRIs and other modern antidepressants. By age group, they found 
small increases among adolescents [83,87] and larger increases in elderly patients [82], but fewer 
completed suicides and more attempts [85].  
However, data from these studies are severely compromised by confounding from morbidity or by 
indication. As already specified, medical treatments, in general, are more likely to be given to more 
severely ill patients who are, therefore, at higher risk of suicide. Treatment with a low risk of toxic 
effects from acute overdosing with the SSRIs means that they are more likely to be prescribed than are 
more toxic agents (such as the tricyclic antidepressants) for patients at increased risk for suicide. 
Additionally, the nonrandomized, clinically-selected treatments in such studies may severely distort 
the associations observed between greater suicidal risk and the use of some treatments.  
5. The Relationship between Antidepressants and Suicide as Reported in Randomized 
Controlled Trials (RCTs) 
RCTs should be the most reliable source of data on the effects of antidepressant treatment on 
suicidal risk. However, individual trials are unlikely to include enough patients with identified suicidal 
actions to allow testing for treatment effects, especially since being acutely suicidal is usually a 
criterion for exclusion from such trials.  Pharmaceuticals 2010, 3               
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Meta-analytic methods by combining the results of many studies may yield substantial numbers of 
suicide attempts and even completed suicides. Rates of suicide attempts, and even of completed 
suicides, may be as high in controlled trials as in clinical samples of patients with major depressive 
disorder. Suicide rates taken from large meta-analyses of modern and older antidepressants or placebos 
averaged 862 per 100,000 per year [88–90], or 66-times above the average international general 
population suicide rate of 13 per 100,000 per year [4]. In clinical samples of severely ill major 
depression patients, usually hospitalized patients, the standardized mortality ratio (SMR) for suicide 
compared to the general population was 20-fold higher [15], and among less severely ill depressed 
patients this risk ratio may be about three-times higher [91]. Such high observed rates of suicidal 
behaviors in RCTs reflect exaggeration arising from annualizing rates based on relatively brief 
exposure times (typically 8–12 weeks) in most trials of patients with acute depression and early in the 
course of treatment.  
There have been several recent reports based on pooling data on rates of completed and attempted 
suicide from large numbers of RCTs and subjects involving modern antidepressants, older standard 
agents and placebos [37,44,46,48,88–90,92–96]. With the exception of one report which found a 
significant excess of suicidal acts during treatment with SSRI antidepressants [44], other meta-analyses 
have found only minor differences in rates of suicidal behaviors between depressed patients treated 
with an SSRI, other antidepressants, or a placebo, with an overall tendency toward an apparently 
greater rate with antidepressants. It was assumed that the trials included in the meta-analyses were 
well-randomized and with well-balanced exposures in both the drug and placebo groups throughout the 
duration of the trials.  
In a meta-analysis, Baldessarini et al. [37] reported that the overall pooled Rate Ratio (RR) and its 
95% confidence interval (CI) was 1.42, compared to the null value of RR=1.0 whereas Fergusson et al. 
[44] reported a relatively large RR. The authors concluded that more than 600 depressed patients 
would have to be exposed to an antidepressant drug for approximately two months (or about 100 
treated for a year), early in the course of an episode of acute major depressive disorders, when the 
suicidal risk is particularly high, to yield one excess suicide attempt, and over 4,500 depressed patients 
to yield one excess suicide over the number associated with untreated major depression.  
An FDA review [48] analyzed all available data from 386 controlled trials of modern antidepressant 
drugs involving 112,875 patients with major depressive or other disorders. Most of the identified 
suicidal events involved suicidal ideation, but were of uncertain clinical significance. Reported 
instances of suicides (0.013%) and attempts (0.198%) may be low due to the relatively brief exposure 
times, which averaged only two months. Among adult patients diagnosed with major depressive 
disorder, the observed suicide rate, based on estimated exposure-times averaging eight weeks, was 77 
per 100,000 per year, or only six-times above the general population rate of [4], compared to suicide 
rates of 862 found in similar controlled trials of modern antidepressants as already noted [88–90]. The 
stratifying by age-groups analysis suggested an increased risk of broadly defined “suicidality” (mainly 
ideation) with modern antidepressants versus placebo at younger ages and possible beneficial effects in 
older patients. It is important to note that, based on these data, completed suicide and attempted suicide 
were rare. 
These findings suggest an increased risk of presumably new suicidal ideation with SSRIs and other 
modern antidepressants over placebo among children, adolescents and young adults up to age 24 years Pharmaceuticals 2010, 3               
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and reinforced the initial findings in meta-analyses involving children and adolescents by the UK drug 
regulatory agency [97] and the FDA [94,96].  
The data fail to support an expected overall reduction of risk of suicidal acts during treatment with 
antidepressants of all types, and this suggests that the risk of suicide attempts and perhaps completed 
suicides may be greater during treatment with antidepressants of various types. However, although 
many trials involving patients with depressive disorders found substantially larger reductions in the 
average ratings of suicidal ideation with antidepressants of various types than with placebo   
[90,92,98–100], unfortunately these trials reported subjective data, usually incidental to the main 
purpose of the study, and based on post-hoc assessments of individual items on standard depression 
symptom-rating scales (e.g., Hamilton item 3 or Montgomery-Åsberg item 10).  
RCTs are limited by the potential unreliability of essentially incidental, passive reporting of suicidal 
thoughts or behaviors based on currently typical “adverse event reporting” systems. In addition, the 
relatively short duration of most trials of treatments for acute depression may not provide an adequate 
evaluation of the effects of treatment on suicidal behaviors which are rare, comparable to the long-term 
trials available for clozapine, lithium and anticonvulsants. Another potential source of bias is that 
initial randomization in RCTs can break down during the conduct of trials. Premature, and potentially 
non-random, dropping out, usually a result of the lack of any perceived benefit or the emergence of 
intolerable side effects of the treatment, is routinely found in most RCTs. Observed rates of “suicidal 
events” are rarely corrected for the actual time of exposure of individual patients to specific treatments. 
Such correction for actual adverse event rates (events/persons/weeks) may be important if actual 
exposures are not closely matched across trial treatment arms, particularly when rare events such as 
completed and attempted suicides are involved [101].  
After reviewing all of the data, the FDA demanded warnings about the possible increased of risk of 
suicidal ideation and perhaps behaviors during the treatment of juvenile and young adult patients with 
SSRIs and other modern antidepressants. This decision was based on at least four controlled trials 
[102], one of which was a very large federally-funded trial with an unusually large separation of 
responses to the drug versus placebo [103]. In 12 relatively large trials of SSRIs in juvenile patients 
with major depression, the relative rate of responding to the drug relative to the placebo (RR) averaged 
1.23 and, in 14 much smaller trials of TCAs, the pooled RR of 1.15 was of similarly modest magnitude 
and statistically nonsignificant [102]. The conclusion about the possible worsening of suicidality in 
young antidepressant-treated patients implies that there are clinically developmental differences in 
affective and behavioral responses to antidepressants that require further study, especially with respect 
to the risks of actual suicidal behaviors. 
6. The Relationship between Antidepressants and Suicide in Different Countries  
In recent years, antidepressant prescribing has increased markedly in many developed countries, 
especially after the introduction of the SSRIs in the early 1990s. This might reflect the better 
recognition, treatment and prescribing for depression and also the advantage that these new 
medications rarely result in lethal overdoses. The associations between antidepressants and suicide 
rates differ by country. In Italy, Barbui et al. [104] described the impact of regulatory changes on 
antidepressant consumption in Italy from 1988 to 1996, examining whether the introduction of SSRIs Pharmaceuticals 2010, 3               
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was associated with changes in the overall suicide rates [104]. Data on suicide, available from 1988 to 
1994, showed that, in the seven-year period during which SSRI use rose, male suicide rates increased 
from 9.8 to 10.2 per 100,000 inhabitants while females suicide rates declined from 3.9 to 3.2. The 
authors concluded that, in Italy, there was not any dramatic reduction in the overall suicide rates as a 
result of the increasing prescribing of SSRIs. Guaiana et al. [105] investigated the impact of the 
increasing use of SSRIs and newer antidepressants on suicide rates and reported that, in Italy from 
1983 to 2000, the use of tricyclic antidepressants remained stable while the use of SSRIs and newer 
agents dramatically increased. Suicide rates for males decreased from 1955 to 1974 and subsequently 
increased, reaching a peak in 1985 and then declining. In females, suicide rates remained substantially 
stable until 1978. Suicide by poisoning dropped by nearly 50% from 1986 to 2000. Long-term analysis 
did not indicate that the increase in antidepressant prescribing was accompanied by a reduction in the 
suicide rate. Furthermore, in Italy, newer antidepressants had no impact on the total number of 
admissions for depression, nor on the proportion of all admissions. 
In Sweden, Carlsten et al. [106] performed a time-series analysis using a two-slope model to 
compare suicide rates before and after the introduction of the SSRIs. Antidepressant sales increased in 
men from 4.2 DDD per 1,000 inhabitants per day during 1977–1979 to 21.8 in 1995–1997 and in 
women from 8.8 to 42.4 between the same periods. A particularly rapid acceleration in antidepressant 
sales was observed during the years 1993–1996. Between the two periods, suicide rates decreased in 
men by 30.9% and by 34.0% in women. The slope of suicide rates significantly changed after 1990, 
corresponding to 348 fewer suicides than expected during 1990-1997. This study showed a statistically 
significant change in the slope in suicide rates among men and women that coincided with the 
introduction of the SSRIs in Sweden. However, the advent of SSRIs may explain only part of the 
declining suicide trend because this trend started years before these drugs were introduced. Isacsson 
[10] found that suicide rate decreased by 19% in parallel with the increased use of antidepressants in 
Sweden, Denmark, Norway and Finland. Moreover, in Sweden there was no demographic group with 
regard to age, gender or county in which the suicide rate decreased in the absence of an increased use 
of antidepressants. Thus, the author concluded that the increased use of antidepressants agents 
appeared to be one of the contributing factors to the decrease in the suicide rate. Ohberg et al. [107] 
found that, in Finland from 1990 to 1995, the total suicide rate decreased from 30.3 per 100,000 
inhabitants per year to 27.2. The total consumption of antidepressants drug more than doubled from 
1990 to 1995. The authors concluded that the increased use of SSRIs in Finland coincided with a 
significant decline in suicide mortality. However, suicides using antidepressants showed an upward 
trend. 
Rihmer reported that, in Hungary, where suicide rates were extremely high, the suicide rate steadily 
declined from 45.9 per 100,000 inhabitants per year in 1984 to 32.1 in 1998 [108–110]. This decrease 
occurred together with the implementation of a new system of psychiatric care in which the number of 
outpatient psychiatric departments increased between 1982 and 1998, the number of psychiatrists 
increased between 1986 to 1998, and the number of emergency telephone services increased during the 
same period. Antidepressant consumption, mainly SSRIs, grew approximately fivefold from 1984 to 
1998. In the same period there was a sixfold increase in unemployment, a 25% rise in official estimates 
of alcoholism rates and a 21% increase in divorce, and so the decrease in suicide rates was remarkable. 
However, Rihmer cautioned that suicide rates are affected by many factors, and the association Pharmaceuticals 2010, 3               
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between improved pharmacotherapy for depression and decreased suicide mortality is not easily 
demonstrated. 
Hall and colleagues [111] found that, in Australia between 1991 and 2000, the suicide rate 
decreased markedly in old men and women and increased in young adults, especially in young men, 
yielding a substantially stable total suicide rate. Exposure to antidepressants was higher for women 
than men in all age groups and increased markedly for both men and women, with the largest increases 
among older adults. A significant negative association was observed between antidepressant 
consumption and suicide in women but not in men. However, among both men and women the largest 
declines in suicide occurred in the age groups with the highest exposure to antidepressants.  
Grunebaum et al. [11] showed that, in the United States from 1985 to 1999, the decline in the 
national suicide rate appeared to be associated with a greater use of non-tricyclic antidepressants. 
Suicide rates were already declining before 1985 in the United States, especially in females [112,113]. 
In an ecological analysis over counties in the USA, Gibbons and colleagues [55] found that the overall 
association between antidepressant prescriptions and the suicide rate was not significant for 
prescriptions for SSRIs, but the prescription of other new-generation non-SSRI antidepressants 
(nefazodone hydrochloride, mirtazapine, bupropion hydrochloride, and venlafaxine hydrochloride) was 
associated with lower suicide rates (both within and between counties). Among adolescents, exposure 
to paroxetine and venlafaxine were significantly associated with increased risk [83,85], and so the 
effect of age seems to be critical [45]. 
In the UK, Davis et al. [114] studied whether a higher suicide risk, defined as previous suicide 
attempts or suicidal ideation, influenced the choice of antidepressant prescribed. They found that a risk 
of suicide did not prevent the prescription of venlafaxine, and that venlafaxine therapy is considered to 
be acceptable and is appropriately managed.  
Also in the UK, Gunnell et al. [115] reported a time-series analysis which documented an increase 
in young male suicide in England and Wales in the last 30 years, in parallel with a rise in a number of 
risk factors for suicide in this age group. In people aged over 60 an association was found between 
increases in the gross domestic product, antidepressant prescribing and other measures of improved 
healthcare provision and a decline in suicide. Also in England, Morgan et al. [119] found that the 
increased prescribing of antidepressants, a proxy measure of improved diagnosis and treatment of 
depression in primary care, was accompanied by lower suicide rates. 
Kasper  et al. [116], in a longitudinal analyses of pooled data from 15 placebo-controlled, 
randomized, double-blind, short-term trials of mirtazapine conducted in Austria, found that 
mirtazapine was associated with statistically significantly lower suicidality risk compared to placebo. 
In the pediatric population, higher SSRI prescription rates have been found to be associated with 
lower suicide rates in children and adolescents [56]. Similar findings were reported by Olfson and 
colleagues [83] in an extensive analysis of prescription data in the USA. However, all these positive 
finding may reflect not only the efficacy of SSRIs, but also better compliance and quality of mental 
health care and a low toxicity in the event of a suicide attempt by overdose.  
In Northern Ireland, Kelly et al. [117] observed that, in the younger age groups, there was no 
association between antidepressant prescribing and suicide, while for the older age groups increased 
antidepressants prescribing was associated with a reduction in the suicide rate over a period of 10 
years. However, a subsequent analysis of British data suggested that the decline in suicide rates Pharmaceuticals 2010, 3               
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happened before the increase in prescribing. Moreover, rises in antidepressant prescribing did not 
consistently coincide with clear changes in suicide trends [118].  
In Iceland sales of antidepressants increased from 1975 to 2000, but suicide rates fluctuated during 
the period of 1950-2000 and did not show any definite trend [54]. 
Finally, in Israel, the prescribing of antidepressants, particularly of SSRIs, increased 2.6-fold 
between 1998 and 2002. An overall reduction in suicides was reported in association with this 
increased rate of antidepressant prescription [120], but was statistically significant only for elderly 
men. 
7. Possible Explanations for the Lack of Effect on Suicidal Risk during Antidepressant 
Treatment and Clinical Implications 
Several explanations for the eventual lack of overall beneficial effect on the rate of completed and 
attempted suicide during antidepressant treatment have been proposed, including limitations to the 
clinical effectiveness of antidepressants, particularly in younger age-groups, and for some features of 
depressive illnesses that may be particularly relevant to suicidal risk, as well as technical limitations of 
the studies of antidepressant treatment and suicide [36]. An additional possibility is that 
antidepressants may have both beneficial and adverse effects, with a net zero average impact on 
suicidal rates.  
These conclusions are supported by the long tradition of clinical observation, including the proposal 
that temporal separation of the relatively early energizing effects of mood-elevating drugs from later 
benefits on the anhedonic features of depression might increase the risk of suicidal behaviors during 
recovery from acute major depressive episodes [121]. Additionally, there are a series of clinical 
observations of newly emerging aggressive and suicidal preoccupations or behaviors among patients 
being treated with antidepressants. Whether such reactions may be more frequent with modern SSRIs 
than with the older antidepressants such as tricyclics (TCAs) is still unclear.  
It is well-known that antidepressant treatment is associated with over-stimulation, restlessness 
resembling akathisia, agitation, insomnia, severe anxiety, mixed-dysphoric bipolar states, or psychosis 
in some patients [122–126]. Such paradoxical effects of antidepressant treatment have received 
attention in recent international discussions of risk/benefit considerations arising from studies of 
SSRIs, particularly when used for depressive disorders in adolescents. These discussions weigh the 
seemingly limited benefits of all types of antidepressant treatment for adolescent depression against 
concern about potential increases in suicidality [127].  
The scientific and clinical significance of the effects of antidepressant treatment on suicidal risk 
requires further critical study, but our clinical impression is that antidepressant treatment may present 
certain behavioral risks that require close clinical monitoring, ongoing differential clinical assessment 
and adequate interventions in order to optimize the effectiveness and safety of antidepressant 
treatment. Several warning signs, including prominent anxiety and irritability, anger or agitation, or the 
appearance of these emotions early in the use of an antidepressant, particularly in antidepressant 
monotherapy, should be assessed and guide clinicians when treating patients with a high suicidal risk. 
Those with likely or suspected bipolar features or psychotic illnesses call for particular concern for Pharmaceuticals 2010, 3               
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potential behavioral risks under antidepressant monotherapy, without the presumably protective effects 
of mood-stabilizing or antipsychotic agents.  
8. The Adverse Effect of Antidepressants and Suicide Mortality 
In 2004, two systematic reviews about the efficacy and safety data of antidepressants for children 
and adolescents were published simultaneously, one in The British Medical Journal [128] and the 
other in The Lancet [127]. Jureidini et al. [128] checked the quality of methods of reported published 
trials of antidepressants drugs in children and adolescents, involving a total of 477 patients from six 
randomized trials who were treated with paroxetine, fluoxetine, sertraline or venlafaxine and 464 
treated with placebo. Of 42 reported outcome measures, only 14 showed a statistical advantage for 
antidepressant drugs. Regarding the adverse effects of treatment, the authors suggested that some 
adverse effects might be more frequent than the authors of the individual studies imply. For example, 
up to half of young patients experienced an “activation syndrome”, and self-injurious ideation was 
seen in 6% of patients [129]. However, this analysis did not investigate the relative frequency of this 
rare outcome. In the second review, Whittington et al. [127] reported no increased risk of suicidal 
behavior with fluoxetine compared to placebo (3.6% versus 3.8%), but an increased risk of suicidal 
ideation or attempting suicide was observed for paroxetine (3.7% versus 2.5%), sertraline (2.6% versus 
1.2%), citalopram (7.1% versus 3.6%,) and venlafaxine (7.7% versus 0.6%).  
In a epidemiological study, Jick and collegues [71] followed 172,598 people who had at least one 
prescription for one of 10 antidepressant drugs in general practice in the UK. They found that the risk 
of suicide was higher in people who received fluoxetine (19 per 10,000 person years, 95%CI 9 to 34) 
than in those receiving dosulepine (dothiepin). In a nested case-controlled subgroup analysis in people 
with no history of suicidal behavior or previous antidepressant prescription, the risk remained the 
same, although the confidence interval broadened to make the result nonsignificant. However, the 
association between the adverse events in patients taking antidepressants and the risk of suicide was 
not reported.  
Jick and colleagues [72] performed a matched case-control study of more than 2,500 patients and 
reported that the risk of suicidal behavior after starting antidepressant treatment was similar among 
users of amitriptyline, fluoxetine, and paroxetine compared with the risk among users of dothiepin. 
The risk of suicidal behavior was similar in patients taking SSRIs and tricyclics, but dothiepin might 
not be a useful comparison antidepressant for countries where this agent has never been licensed, such 
as Italy and the USA [130]. 
To replicate this finding, Jick et al. [72] used amitriptyline as a reference compound, and the OR for 
non-fatal suicidal behaviors among users of the other three antidepressants were 1.21 (0.80–1.83) for 
dothiepin, 1.40 (0.92–2.13) for fluoxetine and 1.55 (0.99–2.43) for paroxetine. A borderline value for 
paroxetine in comparison with amitriptyline emerged in this post-hoc analysis, leaving the possibility 
of an increased risk of non-fatal suicidal behaviors in users of this agent. 
To test the potential empirical link between antidepressant treatment and suicide attempts Valuck 
and colleagues [131] investigated 24,000 adolescents using a community sample of managed-care 
enrollees in the USA. Crude suicide attempt rates ranged from 0.0% to 2.3% by index treatment group. 
Treatment with SSRIs (hazard ratio 1.59), other antidepressant drugs (hazard ratio 1.03) or multiple Pharmaceuticals 2010, 3               
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antidepressants (hazard ratio 1.43) resulted in no significant increased risk of a suicide attempt. In 
contrast, Martinez et al. [80] analyzed the risk of non-fatal self-harm and suicide in 146,095 patients 
with a new diagnosis of depression who were prescribed SSRIs or tricyclics and reported that tricyclic 
users were not at increased risk of suicide or non-fatal self-harm. However, in patients aged 18 or less, 
weak evidence suggested a higher risk of non-fatal self-harm in those prescribed SSRIs (OR 1.59). 
Søndergård  et al. [87] investigated the association between SSRIs and suicide in children and 
adolescents in Denmark and observed a statistically nonsignificant increased rate of suicide associated 
with SSRI use (RR 4.47). Simon et al. [84] identified more than 65,000 individuals with more than 
82,000 episodes of antidepressant treatment. The risk of completed suicide during the acute-phase 
treatment was one in 3,000 treatment episodes, and the risk of a serious suicide attempt was one in 
1,000. The data did not indicate a significant increase in risk of completed suicide or a serious suicide 
attempt after starting treatment with the newer antidepressants. 
Isacsson et al. [59] analyzed the presence of different antidepressants in the forensic toxicological 
screening of 14,857 suicides compared with those in 26,422 cases of deaths by accident or natural 
causes in Sweden from 1992 to 2000. In the toxicological screening, antidepressants were detected in 
3,096 (20%) of the 14,857 cases of suicide investigated and a total of 3,411 different antidepressants in 
these individuals. Of these, 48% were SSRIs. The number of detections in the 26,422 controls was 
1,538. SSRIs were under-represented compared with other antidepressants (OR 0.83). The differences 
within the SSRIs were insignificant, with the exception of fluvoxamine. The OR for the tricyclics as a 
class (including maprotiline) was 1.01, but it was higher for the class of moclobemide, mianserin, 
mirtazapine, reboxetine and venlafaxine (OR 1.78, 99%CI 1.46–2.16). In 52 cases of suicide in those 
aged less than 15 years, seven were positive for antidepressants (clomipramine, imipramine, 
maprotiline, trimipramine, mianserin and venlafaxine), but no SSRIs were detected. In 326 cases of 
suicide in the 15 to 19 year-old group, there were 13 cases which were positive for antidepressants 
(amitriptyline, clomipramine, trimipramine, citalopram, fluoxetine, sertraline and mirtazapine), and 
SSRIs had lower RR in the suicides compared with non-SSRIs. Thus, the hypothesis that treatment of 
depressed individuals with SSRIs leads to an increased risk of suicide was not supported by this 
analysis of all suicides in Sweden over a period of 9 years. 
In a nationwide cohort study in Finland, Tiihonen et al. [85] calculated the RR of completed 
suicide, suicide attempts leading to hospitalization and overall mortality during tricyclic, SSRI and 
SNRI treatment versus no antidepressant use, after adjusting for possible confounders. In the entire 
cohort, fluoxetine use (RR 0.52) was associated with a lower risk of suicide and venlafaxine (RR 1.61) 
with a higher risk. Among suicidal patients who had ever used antidepressants, the current use of any 
antidepressant was associated with a markedly increased risk of attempted suicide and with a markedly 
decreased risk of completed suicide and death.  
The relationship between venlafaxine use and suicidality was also investigated by Rubino et al. 
[132] who found that patients prescribed venlafaxine were more likely to complete or attempt suicide 
compared with patients prescribed citalopram, fluoxetine and dothiepin, but adjustment for a number 
of possible confounders substantially reduced the excess risk. Finally, Juurlink and colleagues [82] 
explored the relationship between the initiation of SSRIs and completed suicide in older patients. 
During the first month of therapy, SSRI utilization was associated with a nearly fivefold higher risk of 
completed suicide over the other antidepressants (adjusted odds ratio 4.8). The risk was independent of Pharmaceuticals 2010, 3               
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a recent diagnosis of depression or the receipt of psychiatric care, and suicides of a violent nature were 
more common during SSRI therapy. However, the absolute risk of suicide was low, maybe suggesting 
that the response to these agents may induce suicide only in a vulnerable subgroup of patients. 
9. Conclusions  
Research on the possible relationship between pharmacotherapy and suicidal behavior was virtually 
unknown until a decade ago. An initial case series and several reports, especially in the last ten years, 
indicated that a minority of depressed patients experience adverse behavioral and emotional responses 
to treatment with various antidepressant drugs, including SSRIs [38,123,133]. Some ecological studies 
reported minor decreases of suicide rates by region or over time associated with higher rates of 
prescribing modern antidepressants, but these correlations are presumably influenced by many factors, 
including access to clinical care. Most large clinical studies indicate decreased suicidal risk with 
antidepressant treatment, but others find increases for patients in some age groups. However, these 
studies often have confounding variables such as an association between antidepressant treatment and 
more severe depression and, thus, greater suicidal risk. Data pooled from relatively brief, randomized, 
controlled trials in patients with acute major depression suggest an increase in the risk of suicide 
attempts, as well as increases in suicidal ideation in younger patients and decreases in elderly patients.  
These data, taken together, suggest that antidepressants do not always have a beneficial effect on 
the risk of suicidal behavior, although they may reduce both suicidal ideation and other depressive 
symptoms. Peculiar responses, often emerging early in the course of antidepressant treatment, require 
close clinical follow-up in order to assess the risk of suicide. When this risk is present, treatment 
should be appropriately modified, for example, by changing antidepressant medication, adding 
sedating, antipsychotic or mood-stabilizing treatments, and providing additional individual support. 
Suggested pharmacological interventions and other clinical steps aimed at safe management of 
patients at risk for the types of adverse behavioral responses to antidepressants have been described as 
follows. First, it is crucial to decrease the dose, or suspend antidepressant therapy, if agitation, 
insomnia or anger emerge. In addition, clinicians should introduce an atypical antipsychotic, 
anticonvulsant or sedative, and consider lithium for cooperative patients, especially following an 
inadequate antidepressant response. The collaborative and flexible nature of treatment required must 
emphasize the clinician’s availability for extra visits or contacts, especially in emergencies. Clinicians 
should express explicit concern for growing discomfort and despair; address suicidality directly and 
repeatedly; monitor for access to lethal means of self-injury; enlist the help of a family member to 
monitor the patient; and dispense appropriate medicines. 
We conclude that antidepressant drugs generally appear to reduce suicidal ideation in depressed 
adults, but whether these agents impact suicidality in younger patients with major affective disorders is 
still a matter of debate. The possible increased suicide rate induced by the growing utilization of 
antidepressants remains one of the most important public health issues. Clinicians should be vigilant 
about the possible risk of iatrogenesis in prescribing potent drugs such as antidepressants [134]. The 
possible existence, particularly in younger patients, of many unrecognized pseudo-unipolar mixed 
states, which can be a clinical substrate for suicidality, may be one link that explains the increased 
suicide rate associated with the use of antidepressants in adolescent patients.  Pharmaceuticals 2010, 3               
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